Colgate-Palmolive Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Colgate Palmolive (CL) Stock Fair Value Edges Higher After Q3 Earnings Beat

Analyst upgrade Earnings report AI-generated analysis

πŸ“ˆ Colgate-Palmolive beat Q3 2026 earnings expectations and raised FY26 guidance against a subdued backdrop.

πŸ’° UBS, Morgan Stanley, and BNP Paribas raised price targets to the US$108-US$112 range reflecting confidence in execution.

πŸ“‰ Piper Sandler flags ongoing pressure in U.S. category momentum and inventory headwinds from e-commerce shifts.

βš–οΈ Barclays and Wells Fargo maintain Equal Weight ratings but lifted price targets to US$95.

πŸ’΅ Simply Wall St raised its fair value estimate for CL from US$98.80 to US$101.70.

πŸ“Š Revenue growth assumptions are set at 2.75% with net profit margins adjusted up to 15.09%.

πŸ€– The company leverages SGPP cost savings and AI tools like Promo AI to fund reinvestment and maintain profitability.

⚠️ Key risks include softer category growth in North America and ongoing legal action over toothpaste tube recyclability.

Bullish Signals
  • Colgate-Palmolive delivered a Q3 2026 earnings beat and raised FY26 guidance against subdued expectations, signaling strong execution.
  • Major analysts including UBS, Morgan Stanley, and BNP Paribas increased price targets to the US$108-US$112 range due to better-than-expected sales and margin performance.
  • Goldman Sachs highlighted the earnings beat and guidance raise as signs of strong execution in a challenging operating environment.
Risk Factors
  • Piper Sandler warns of ongoing pressure in U.S. category momentum and expects continued inventory headwinds as business shifts to e-commerce.
  • Barclays and Wells Fargo maintain Equal Weight ratings, indicating a balanced but cautious stance despite lifting price targets.
Full Analysis
Colgate-Palmolive (CL) shares are supported by a recent Q3 2026 earnings beat and updated guidance that exceeded subdued market expectations. Major investment banks, including UBS, Morgan Stanley, and BNP Paribas, have raised their price targets to the US$108-US$112 range, citing strong execution in a challenging operating backdrop. Goldman Sachs specifically highlighted the company's ability to raise full-year 2026 guidance as evidence of robust performance. Analyst sentiment remains mixed regarding near-term growth prospects due to specific headwinds. Piper Sandler warns of ongoing pressure in U.S. category momentum and expects continued inventory challenges as business shifts toward e-commerce and retailers adjust stock levels. While Barclays and Wells Fargo maintain Equal Weight ratings, they lifted their price targets to US$95, reflecting a balanced but cautious stance on the stock's immediate trajectory. Simply Wall St has adjusted its fair value estimate for Colgate-Palmolive from US$98.80 to US$101.70, indicating a modest uplift in valuation. The model assumes revenue growth of 2.75% and a net profit margin expansion to 15.09%, while keeping the future P/E ratio stable at approximately 27.4x. Key strategic drivers include the company's reliance on premium oral care lines, SGPP cost savings initiatives, and AI-driven tools like Promo AI to fund reinvestment and support profitability.